Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
NVNovavax, Inc. logo

Novavax, Inc. (NVAX)

NASDAQ Global Select · Currency in USD
$9.70 ▼ -0.29 (-2.90%)
At close: Oct 23, 4:00 PM ET. Market closed.
$9.70 ▲ +0.00 (+0.01%)
After hours: Oct 23, 7:52 PM ET

Summary

Previous Close
$9.99
Open
$9.84
Day's Range
$9.62 – $9.93
52 Week Range
$6.20 – $13.39
Volume
4,418,715
Avg. Volume
5,548,385
Market Cap
$1.60B
Beta (5Y Monthly)
2.44
PE Ratio (TTM)
--
EPS (TTM)
-$1.51
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$18.00

Profile: Novavax, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
749
CEO
John Charles Jacobs

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.22 · Revenue est. $74.62M
DateEst.Actual
Aug 6, 2026-$0.38-$0.32Beat
May 6, 2026-$0.25-$0.06Beat
Feb 26, 2026-$0.66$0.11Beat
Nov 6, 2025-$1.08-$1.25Miss
Aug 6, 2025-$0.07$0.62Beat
May 8, 2025$0.71$2.93Beat

Analyst view

Consensus price target
$18.00 ▲ +85.6%
Range $11.00 – $25.00
Rating: Buy
Buy 70% · Hold 13% · Sell 17%

Get free alerts on NVAX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.